Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine + HAG for relapsed/refractory pediatric AML (single-arm, open-label, multicenter)
ChiCTR2000038340Phase 4Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete response (CR + CRi) rate after 1 course of CHAG treatment. Started Sep 2020; status: recruiting.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000038340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038340.